NeuExcell Therapeutics Raises Over $10M in Series Pre-A Funding
- NeuExcell Therapeutics, China-based gene therapy company focusing on neurodegenerative diseases, raised $10+m in Series Pre-A financing
- The round was led by Co-Win Ventures, joined by other institutional investors YuanBio, Oriza Seed, Tsingyuan and InnoAngel
- With the closing of this Pre-A round, Dr. Xin Huang, managing partner at Co-Win Ventures and Jonathan Sun joined the Board of Directors
- The company intends to use the funds to continue to expand its development efforts
- NeuExcell is an early-stage gene technology company which aims to improve the lives of patients suffering from neurodegenerative diseases and CNS injuries
- The company has developed neural repair technology through astrocyte-to-neuron conversion in vivo by introducing neural transcription factor(s) through adeno-associated virus (AAV)-based gene therapy
